Adjuvant Trastuzumab for 9 Weeks vs 1 Year With Chemotherapy for Early HER2 -Positive Breast Cancer

This randomized clinical trial evaluates the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy for a duration of 9 weeks vs 1 year in women with HER2-positive early breast cancer treated with up-front chemotherapy containing a taxane and trastuzumab.

https://ift.tt/2JlBHeH